NCT06343792View on ClinicalTrials.gov

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Steroid Refractory GVHD
Interventions
DRUG

RLS-0071

RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Trial Locations (8)

30041

RECRUITING

Site 1318, Atlanta

41013

RECRUITING

Site 3101, Seville

43210

RECRUITING

Site 1382, Columbus

45229

RECRUITING

Site 1100, Cincinnati

63110

RECRUITING

Site 1068, St Louis

79106

RECRUITING

Site 3242, Freiburg im Breisgau

90095

RECRUITING

Site 1343, Los Angeles

91010

RECRUITING

Site 0191, Duarte

Sponsors
All Listed Sponsors
collaborator

CTI Clinical Trial and Consulting Services

OTHER

lead

ReAlta Life Sciences, Inc.

INDUSTRY